Image via Simply Wall St
Neurocrine Biosciences: Product Launch
Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Source: Simply Wall St
The leadership read
Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
Market context: The wider read — a Talent Market Index of 110 (Hot), up 11.7 month-on-month — shows Americas signal flow easing (-12.5pts).
Neurocrine Biosciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 21 tracked companies; 0.1% of MitchelLake's Americas signal flow.
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Partnership · Americas
Ratio Therapeutics →Ratio Therapeutics expanded manufacturing collaboration with PharmaLogic to add capacity and redundancy for clinical development of lead radiotherapeutic candidate BOSTON
Intelligence powered by Autonodal ↗